Muramyl Tripeptide Plus Chemotherapy Reduces Metastasis in Non-Metastatic Osteosarcoma: A Single-Center Experience

BACKGROUND: The immunomodulator mifamurtide plus a chemotherapy regimen has been shown to significantly improve the outcome in non-metastatic osteosarcoma patients. We report the results of the addition of mifamurtide to chemotherapy in newly diagnosed patients with osteosarcoma. METHODS: A total of...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Asian Pac J Cancer Prev
Autors principals: Taçyıldız, Nurdan, Ünal, Emel, Dinçaslan, Handan, Çakmak, H Mine, Köse, Kenan, Tanyıldız, Gülşah, Kartal, Ömer
Format: Artigo
Idioma:Inglês
Publicat: West Asia Organization for Cancer Prevention 2020
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7437342/
https://ncbi.nlm.nih.gov/pubmed/32212798
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.31557/APJCP.2020.21.3.715
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars